Risk factors and a predictive model for acute hepatic failure after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma
Authors:
- 17 October 2012
- journal article
- research article
- Published by Wiley in Liver International
- Vol. 33 (2) , 197-202
Abstract
Background/Aims: Acute hepatic failure (AHF) is one of the most serious complications of transcatheter arterial chemoembolization (TACE). The aims of this study were to investigate risk factors of AHF after TACE and to establish a predictive model for AHF.Methods: In the evaluation set, a total of 820 patients who underwent TACE as a first treatment for hepatocellular carcinoma were included. The demographic, laboratory, radiological and treatment‐related factors were analysed to identify risk factors for AHF after TACE and a predictive model was established using the identified risk factors. In the validation set, a different cohort of 438 patients was included to validate the predictive model.Results: The incidence of post‐TACE AHF was 15.1% (124/820). Multivariate analysis revealed that presence of portal vein thrombosis, high aspartate aminotransferase, bilirubin, and log alpha‐foetoprotein levels, and low albumin and sodium levels were independent risk factors. A mathematical model was established using these independent risk factors, and the area under the receiver operating characteristic curve of the model was 0.773 (95% confidence interval, 0.726–0.820). The cut‐off value of 9 had a sensitivity of 78.2%, a specificity of 72.3%, a positive likelihood ratio of 2.82, a negative likelihood ratio of 0.30, a positive predictive value of 28.9% and a negative predictive value of 95.8%.Conclusions: The risk factors of post‐TACE AHF were presence of portal vein thrombosis, high aspartate aminotransferase, bilirubin, and alpha‐foetoprotein levels, and low serum albumin and sodium levels. A mathematical model to predict post‐TACE AHF was established.Keywords
This publication has 25 references indexed in Scilit:
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatology, 2003
- Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinomaHepatology, 2002
- Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trialThe Lancet, 2002
- A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinomaCancer, 2002
- Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL ConferenceJournal of Hepatology, 2001
- The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstructionCancer, 1997
- Factors correlated with portal venous invasion by hepatocellular carcinoma: Univariate and multivariate analyses of 232 resected cases without preoperative treatmentsCancer, 1996
- Risk Factors Linked to Tumor Recurrence of Human Hepatocellular Carcinoma After Hepatic ResectionHepatology, 1992
- Prognostic histologic features of resected small hepatocellular carcinoma (HCC) in Taiwan. A comparison with resected large HCCCancer, 1985